IRS Issues Revised Instructions for Form 6765 (R&D Credit)

The IRS released revised instructions for Form 6765, the Credit for Increasing Research Activities, effective for the 2025 tax year. The updates reflect recent legislative changes under the One Big Beautiful Bill Act (OBBBA), including new Section 174A, and continue the IRS’s push to expand and standardize R&D credit reporting. There is also a critical filing issue tax teams need to know about before they file.

MASSIE Warning

Before diving into the full breakdown, one issue deserves immediate attention for any tax team filing this year.

The revised instructions require current-year QREs to be reported at the filing-member level. Base-period amounts, meaning three prior-year QREs for the alternative simplified credit and four prior-year gross receipts, must be reported at the controlled-group level. That mismatch can produce a credit amount that does not accurately reflect the filing member’s entitlement.

Many expected the IRS to correct this in the latest instructions. It did not. The same problematic language remains. Until the IRS releases a correction, tax teams should follow the form as written and manually override the credit amount on Line 13 for the regular credit or Line 26 for the ASC.

This is not a minor technical point. Missing this override can result in a materially incorrect credit. Review it carefully before filing.

Key Highlights

1. Alignment with new Section 174A (Domestic R&E Expenditures)
The revised instructions add a new discussion of domestic research and experimental (R&E) expenditures under Section 174A. The instructions clarify how R&E costs that are deducted or capitalized/amortized under Section 174A interact with the R&D credit calculation, reinforcing the link between Section 174 treatment and credit eligibility.

2. Updates to the definition of Qualified Research Expenses (QREs)
The definition of QREs has been revised to better align with statutory language under Section 41 and to explicitly reference Section 174A. While the categories of QREs (wages, supplies, contract research, etc.) remain unchanged, the updated language emphasizes consistency between the research credit and Section 174A treatment.

3. Changes to Section 280C coordination
For tax years beginning after January 1, 2025, the instructions clarify that if a taxpayer does not elect the reduced credit under Section 280C, the full gross credit amount must reduce Section 174A expenditures. Prior‑year rules continue to apply for earlier tax years.

4. Section G (Business Component Information) timing and clarifications
Expanded business‑component reporting in Section G remains:

• Optional for tax years beginning before 2026, and
• Mandatory for tax years beginning after 2025, subject to statutory exceptions for certain smaller taxpayers.

The revised instructions also clarify:

• The $50 million gross receipts test (applied over the prior three tax years),
• Updated statutory and regulatory references, and
• Certain mechanics related to reporting thresholds and controlled groups.

5. Amended return and administrative updates
The instructions remove direct references to prior IRS internal guidance on refund claims and instead refer generally to the IRS’s required information for a valid research credit claim. However, existing documentation standards for refund claims remain relevant in practice. The instructions also reiterate administrative guidance on controlled groups, partnerships, and transition relief.

What This Means for Taxpayers

• Companies claiming the R&D credit should review how Section 174A treatment affects both their credit computation and related adjustments.
• Although Section G reporting is not yet mandatory for 2025, taxpayers should begin assessing data availability and processes in anticipation of required reporting for 2026.
• The revised instructions may affect credit computations, documentation practices, and audit readiness, particularly for controlled groups and taxpayers filing amended returns.

Next Steps

Tax teams should evaluate these instruction changes alongside other recent developments affecting R&D costs and credits. Consider whether updates to internal processes or modeling are needed ahead of the compliance cycle. If your team has questions about how the revised instructions affect your specific situation, including the controlled-group override issue, MASSIE can help.